Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Aveanna Healthcare is a leading provider of home healthcare services across 33 states, specializing in pediatric and adult private duty nursing, home health, and hospice care. The company operates a fragmented, labor-intensive business model with approximately 40,000 caregivers serving medically complex patients, primarily reimbursed through Medicaid (60%+) and Medicare programs. Stock performance is driven by nurse staffing levels, state Medicaid rate increases, and census growth in high-acuity pediatric cases.
Aveanna generates revenue by deploying licensed nurses and caregivers to provide in-home care, billing government payers (Medicaid/Medicare 80%+) and managed care organizations at negotiated hourly or episodic rates. Gross margins of 31% reflect the spread between caregiver wages ($18-25/hour) and reimbursement rates ($35-50/hour), with profitability dependent on nurse utilization rates (target 85%+), minimizing overtime costs, and securing state Medicaid rate increases that outpace wage inflation. The company has limited pricing power as rates are largely government-determined, but benefits from high patient switching costs due to care continuity requirements and regulatory barriers (state licensing, accreditation) that limit new entrants.
Nurse staffing levels and wage inflation: Ability to recruit/retain caregivers in tight labor markets directly impacts billable hours and overtime costs
State Medicaid rate adjustments: Annual rate increases in key states (Texas, Florida, Pennsylvania) that represent 40%+ of revenue
Same-store census growth: Patient admissions and retention in high-acuity pediatric private duty segment with $150K+ annual revenue per patient
Managed care contract renewals: Negotiations with major payers (UnitedHealth, Anthem, Centene) affecting 20% of revenue mix
M&A activity: Tuck-in acquisitions of regional home health agencies at 6-8x EBITDA multiples to expand geographic footprint
Medicaid reimbursement pressure: State budget constraints and shift to managed care models create ongoing rate pressure, with 15+ states implementing rate freezes or cuts in recent years
Chronic nurse shortage: Structural labor supply constraints in nursing profession (aging workforce, limited nursing school capacity) drive sustained wage inflation of 4-6% annually, outpacing reimbursement growth
Regulatory complexity: Operating across 33 states requires managing disparate licensing requirements, Medicaid programs, and compliance standards, with penalties for violations reaching $10M+ annually
Fragmented market with 10,000+ home health agencies creates intense local competition for both patients and nurses, limiting pricing power and driving wage bidding wars
Large national competitors (Amedisys, LHC Group/UnitedHealth, Encompass Health) have greater scale advantages in payer negotiations and technology investments
Hospital systems vertically integrating home health services to capture post-acute care margins, bypassing independent providers
High leverage at 5.3x net debt/EBITDA with $800M term loan limits financial flexibility and requires $120M+ annual debt service, consuming most free cash flow
Negative equity position (-$136% ROE) from leveraged buyout capital structure creates refinancing risk if EBITDA deteriorates
Working capital intensity with 60+ day DSO on Medicaid receivables requires $150M+ in working capital, straining liquidity during growth phases
low - Home healthcare demand is non-discretionary and driven by chronic disease prevalence, aging demographics, and hospital discharge patterns rather than GDP growth. Medicaid/Medicare reimbursement provides revenue stability through economic cycles. However, state budget pressures during recessions can delay Medicaid rate increases, and unemployment spikes may temporarily improve nurse labor supply.
Rising interest rates increase borrowing costs on the company's $800M+ debt load (primarily variable-rate term loans), directly pressuring free cash flow and limiting M&A capacity. Higher rates also compress valuation multiples for healthcare services stocks trading at 10-12x EV/EBITDA. Conversely, rate cuts improve refinancing opportunities and reduce annual interest expense by $5-10M per 100bps decrease.
Moderate exposure to credit conditions through two channels: (1) Tighter credit markets limit access to acquisition financing, slowing the roll-up strategy critical for scale in fragmented markets, and (2) Medicaid managed care organizations may delay payments or negotiate harder on rates during credit stress, extending DSO and pressuring working capital.
value - Stock trades at 0.7x P/S and 10.2x EV/EBITDA, below healthcare services peers at 1.2x P/S and 13x EV/EBITDA, attracting investors betting on operational turnaround, margin expansion from labor cost stabilization, and deleveraging. The 45% one-year return reflects recovery from COVID-era staffing disruptions, but negative net margin and high leverage deter growth investors. Recent 92% EPS growth suggests inflection point, appealing to deep-value funds focused on healthcare services consolidation.
high - Small-cap healthcare services stock with $1.5B market cap exhibits elevated volatility (estimated beta 1.3-1.5x) driven by quarterly earnings surprises from nurse staffing fluctuations, Medicaid rate announcement timing, and leverage concerns. Recent 3-month decline of -14.6% despite strong 1-year performance demonstrates sensitivity to labor market data and interest rate expectations. Illiquidity in trading amplifies price swings around earnings releases.
